Literature DB >> 9293679

Sucralfate cream in the management of moist desquamation during radiotherapy.

G Delaney1, R Fisher, C Hook, M Barton.   

Abstract

Randomized trials have shown that sucralfate is effective in the management of acute radiation reactions such as oesophagitis, mucositis and proctitis. However, at the time of commencement of the present trial, it had never been used in the management of moist desquamation of the skin. The purpose of the present study was to assess the value of sucralfate cream in the management of moist desquamation during radiotherapy. Patients who developed moist desquamation during radiation were eligible. Patients were stratified by site of radiotherapy into three groups: (i) the head and neck; (ii) the breast; and (iii) other sites. Patients were randomized to receive 10% sucralfate in sorbolene cream or sorbolene alone. Patients' pain and skin healing were assessed by using linear analogue self-assessment (LASA) scales and by serial measurement of the desquamated area. Due to poor patient accrual, the trial was terminated after 2 years and 39 patients. No statistically significant difference was found between the two arms in either time from randomization to healing or improvement in pain score. Twenty patients in the sucralfate arm took a geometric mean of 14.8 days to heal whereas 19 patients receiving sorbolene alone took a geometric mean of 14.2 days. The ratio of mean times of healing, 1.043, is not statistically different from 1 (P = 0.86; 95% CI = 0.65, 1.67). A total of 75% of the patients reported pain relief on application of either cream. Mean LASA scores for pain for each day after randomization were compared by treatment arm and there was no statistically significant difference (P = 0.32). The present trial was unable to show a difference in terms of time to healing or pain relief in the treatment of moist desquamation. The small number of patients in the trial gave a wide confidence interval for treatment difference, implying that an important effect of sucralfate has not been excluded. Given the poor accrual in the present, single-institution study, future studies may need to be multi-institutional and we encourage other centres to perform randomized trials in the management of moist desquamation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9293679     DOI: 10.1111/j.1440-1673.1997.tb00672.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  10 in total

Review 1.  The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline.

Authors:  Amanda Bolderston; Nancy S Lloyd; Rebecca K S Wong; Lori Holden; Linda Robb-Blenderman
Journal:  Support Care Cancer       Date:  2006-06-07       Impact factor: 3.603

Review 2.  Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.

Authors:  Rebecca K S Wong; René-Jean Bensadoun; Christine B Boers-Doets; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2013-08-14       Impact factor: 3.603

Review 3.  [Topical pain therapy in oral mucositis: a systematic review].

Authors:  H Bornemann-Cimenti; S K Kobald; I S Szilagyi; A Sandner-Kiesling
Journal:  Schmerz       Date:  2013-06       Impact factor: 1.107

Review 4.  A systematic review of patient-rated measures of radiodermatitis in breast cancer radiotherapy.

Authors:  Julie B Schnur; Bianca Love; Bari L Scheckner; Sheryl Green; A Gabriella Wernicke; A Gabriella; Guy H Montgomery
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

Review 5.  Topical agent therapy for prevention and treatment of radiodermatitis: a meta-analysis.

Authors:  Yuejiao Zhang; Shoude Zhang; Xiaoling Shao
Journal:  Support Care Cancer       Date:  2012-10-12       Impact factor: 3.603

6.  Sucralfate gel as a radioprotector against radiation induced dermatitis in a hypo-fractionated schedule: a non-randomized study.

Authors:  V Kouloulias; C Asimakopoulos; M Tolia; G Filippou; K Platoni; M Dilvoi; I Beli; J Georgakopoulos; G Patatoukas; N Kelekis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

7.  The effects of tea extracts on proinflammatory signaling.

Authors:  Frank Pajonk; Anja Riedisser; Michael Henke; William H McBride; Bernd Fiebich
Journal:  BMC Med       Date:  2006-12-01       Impact factor: 8.775

Review 8.  Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Raymond Javan Chan; Joan Webster; Bryan Chung; Louise Marquart; Muhtashimuddin Ahmed; Stuart Garantziotis
Journal:  BMC Cancer       Date:  2014-01-31       Impact factor: 4.430

9.  Efficacy of topical sucralfate vERSUs silver sulfadiazine in the management of burns: A 1-year randomized controlled trial.

Authors:  A S Godhi; P Ram; R Powar
Journal:  J West Afr Coll Surg       Date:  2017 Jan-Mar

10.  Randomized controlled trial of topical mupirocin versus mupirocin with sucralfate combination in chronic skin ulcers.

Authors:  Subhrangsu Chatterjee; Sumit Sen; Avijit Hazra; Amal Kanti Das
Journal:  Indian J Pharmacol       Date:  2019-11-26       Impact factor: 1.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.